Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration

Ophthalmic Research

Volumn 46, Issue 3, 2011, Pages 152-159

  Querques, Giuseppe ^a   Forte, Raimondo ^a   Berboucha, Elya ^a   Martinelli, Domenico ^a   Coscas, Gabriel ^a   Soubrane, Gisele ^a   Souied, Eric H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Age related macular degeneration; Optical coherence tomography; Ranibizumab; Spectral domain; Time domain; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; THICKNESS; TIME DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CYSTS; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PIGMENT EPITHELIUM OF EYE; RETINAL DETACHMENT; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 79952329875     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000325027     Document Type: Article

References (21)

1. Fung AE, Lalwani GA, Rosenfeld PJ, et al: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
2. Lalwani GA, Rosenfeld PJ, Fung AE, et al: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the Pronto Study. Am J Ophthalmol 2009;148:43-58.
3. Schmidt-Erfurth U, Leitgeb RA, Michels S, et al: Three dimensional ultra-high resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 2005;46:3393-3402. (Pubitemid 44264330)
4. Krebs I, Hagen S, Brannath W, Haas P, Womastek I, de Salvo G, Ansari-Shahrezaei S, Binder S: Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. Ophthalmology 2010;117:1577-1584.
5. Chen TC, Cense B, Pierce MC, et al: Spectraldomain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol 2005;123:1715-1720. (Pubitemid 41785106)
6. Nassif N, Cense B, Park BH, et al: In vivo human retinal imaging by ultra-high speed spectral domain optical coherence tomography. Opt Lett 2004;29:480-482.
7. Jaffe GJ, Caprioli J: Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 2004;137:156-169. (Pubitemid 38045202)
8. Taban M, Sharma S, Williams DR, Waheed N, Kaiser PK: Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements. Ophthalmology 2009;116:964-970.
9. Drexler W, Sattmann H, Hermann B, et al: Enhanced visualization of macular pathology with the use of ultra-high resolution optical coherence tomography. Arch Ophthalmol 2003;121:695-706. (Pubitemid 36554473)
10. Costa RA, Calucci D, Skaf M, et al: Optical coherence tomography. 3. Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-2406. (Pubitemid 38902615)
11. Pons ME, Garcia-Valenzuela E: Redefining the limit of the outer retina in optical coherence tomography scans. Ophthalmology 2005;112:1079-1085. (Pubitemid 40797465)
12. Han IC, Jaffe GJ: Comparison of spectraland time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol 2009;147:847-858.
13. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
14. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
15. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, Diabetic Retinopathy Clinical Research Network: Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008;115:1366-1371.
16. Forte R, Cennamo GL, Finelli ML, de Crecchio G: Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 2009;23:2071-2078.
17. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, Wolf S: Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-3437.
18. Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S, Ansari-Shahrezaei S, Binder S: Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. Invest Ophthalmol Vis Sci 2009;50:995-1000.
19. Keane PA, Bhatti RA, Brubaker JW, Liakopoulos S, Sadda SR, Walsh AC: Comparison of clinically relevant findings from highspeed Fourier-domain and conventional time-domain optical coherence tomography. Am J Ophthalmol 2009;148:242-248.
20. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK: Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116:947-955.
21. Mylonas G, Ahlers C, Malamos P, Golbaz I, Deak G, Schuetze C, Sacu S, Schmidt-Erfurth U: Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol. 2009;93:1453-1460.